Polymer–drug conjugates have long been a mainstay of the drug delivery field, with several
conjugates successfully translated into clinical practice. The conjugation of therapeutic …

The effectiveness of anticancer drugs in treating a solid tumour is dependent on delivery of
the drug to virtually all cancer cells in the tumour. The distribution of drug in tumour tissue …

Peptide–and protein–nanoparticle conjugates have emerged as powerful tools for
biomedical applications, enabling the treatment, diagnosis, and prevention of disease. In …

Cancer along with cardiovascular disease are the main causes of death in the industrialised
countries around the World. Conventional cancer treatments are losing their therapeutic …

The application of nanoparticles (NPs) to drug delivery has led to the development of novel
nanotherapeutics for the treatment of various diseases including cancer. However, clinical …

Peptide–drug conjugates (PDCs) represent an important class of therapeutic agents that
combine one or more drug molecules with a short peptide through a biodegradable linker …

Elastin-like polypeptides (ELPs) are stimulus-responsive biopolymers derived from human
elastin. Their unique properties—including lower critical solution temperature phase …

Thermoresponsive polymers constitute an important class of materials for biomedical
application due to their thermally reversible coil-to-globule transition which can be exploited …

Cancer remains one of the world's leading causes of death. However, most conventional
chemotherapeutic drugs only show a narrow therapeutic window in patients because of their …

Although immune checkpoint blockade has shown initial success for various cancers, only a
small subset of patients benefits from this therapy. Some chemotherapeutic drugs have been …